Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. - Wikidata - awgldk - TriplyDB

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.

http://www.wikidata.org/entity/Q35431110

about

Prevention and treatment of bone fragility in cancer patient Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies Oral bisphosphonate use and risk of postmenopausal endometrial cancer.Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate Risks and Benefits of Bisphosphonate Therapies.Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.Subtrochanteric femoral stress fracture with features of atypical femoral fracture in patient with Paget's disease: a case report.Bisphosphonate conjugation for bone specific drug targeting.

P2860

Q26775765-90C34679-F530-4334-B049-621991F65485 Q26782621-2274DB6E-9AFD-47BA-A365-C179393AF367 Q28087279-71B9CE70-07BC-497C-960C-F26861476E9E Q35215054-915DBBDD-FAD1-4C43-AD21-B4B66D852FBD Q35610546-CEF3FEF0-B4E6-401F-A3A6-08D255805909 Q36759195-4C5F244C-6749-4BE2-9488-8D66B2BA8D75 Q38533828-7A33C3C7-F844-4CD8-8E0F-3850FC97BBC6 Q46277856-43554C07-FF4A-4615-993A-1F1C4AECCB97 Q49465302-92378CBF-8FBE-4EF8-A232-686E58DF22B0 Q55515922-E25F8DAB-9B72-4532-97A1-811822BA39AD

P2860

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.

http://www.wikidata.org/entity/Q35431110

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@ast

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@en

type

label

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@ast

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@en

prefLabel

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@ast

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@en

P1433

Q35431110-E100D124-6617-4933-BAC7-79AE9F1D6D9F

P1476

Q35431110-B07C2B69-5B67-48D9-8A00-3047050E576F

P2093

Q35431110-22502F55-B111-4572-856A-A1C8422D9CFB

Q35431110-6C9A4E78-4845-4779-8E6D-A03D7966BCE9

Q35431110-7655044B-9702-4D03-B561-6396FE3B45BB

Q35431110-8ADBC569-BEAF-4F69-948E-5950CBADC7FF

Q35431110-931AA2C3-5096-474E-BEEA-1D2FE83F0654

P2860

Q35431110-04B724D5-90BA-48CD-BD59-615FB68FC055

Q35431110-0AB1921E-E105-4225-98E4-358A9E2C8A1F

Q35431110-0C1988AC-21D1-410B-8815-E638B6A6321F

Q35431110-0C4A586C-63C4-4E0B-AF26-DBCECCB19944

Q35431110-1694AFC1-BD39-41E3-9821-BAEEDA9CEA91

Q35431110-1B74E943-06F8-4F77-9698-DDE913E31890

Q35431110-23D59428-DE2F-4153-962B-807C5DAA3395

Q35431110-298C783C-E75F-4510-9D69-95CE951F377C

Q35431110-2AB2ED0F-469A-4891-9055-BC9A45981D93

Q35431110-2EE5F643-2562-4AC0-8619-F367BFBEAAA3

P304

Q35431110-AD7F35E7-1640-4155-AE12-7130D8739421

P31

Q35431110-2853FDD7-4CC1-483B-A78D-82B11ECCE6CE

P356

Q35431110-606887D3-830C-4A80-9E9A-8CD70FDB23CB

P433

Q35431110-6AA40CB0-307D-4EDF-B5A9-7275C2405AF7

P478

Q35431110-EB02040B-3DC8-427D-99E8-646550017D08

P50

Q35431110-935C5351-C1ED-4476-8BB9-BF5FD4BCB5D5

Q35431110-DAB76402-852F-44FE-A06D-1E272FED3F83

P577

Q35431110-F067434A-3F4C-4B44-921A-1F95F4646413

P5875

Q35431110-87053591-143D-4809-AC98-F8AFC4954648

P698

Q35431110-F9555DCC-7FB3-458A-8C30-277FF97F0AA2

P932

Q35431110-809647A8-7EC2-475E-BCBB-B43448A763B9

P356

JAMAINTERNMED.2014.3634

P1433

JAMA Internal Medicine

P1476

Effect of bisphosphonate use o ...... endronate and zoledronic acid.

@en

P2093

Dennis M Black

http://www.w3.org/2001/XMLSchema#string

Douglas C Bauer

http://www.w3.org/2001/XMLSchema#string

Kristine E Ensrud

http://www.w3.org/2001/XMLSchema#string

Steven R Cummings

http://www.w3.org/2001/XMLSchema#string

Trisha F Hue

http://www.w3.org/2001/XMLSchema#string

P2860

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group.

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.

Hormone therapy to prevent disease and prolong life in postmenopausal women.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

P304

1550-1557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAINTERNMED.2014.3634

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Barrett-Connor

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264627544

http://www.w3.org/2001/XMLSchema#string

P698

25111880

http://www.w3.org/2001/XMLSchema#string

P932

4398333

http://www.w3.org/2001/XMLSchema#string